Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
Our resource hub to discover reports, policy papers and other forms of informative content
This submission responds to PMPRB’s consultation on its proposed Guideline Monitoring and Evaluation Plan GMEP, deeming it premature.
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.
The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.
IMC recommends striking a balance among affordability and access to innovative medicines and vaccines, allocating more funding and research incentives over five years, and developing a national life sciences strategy.